Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-Resistant Hypertension Clear all
Not yet recruiting Phase 2 Interventional

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT07473700
View directory record Official record
Conditions
Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions
TX000045
Drug
Lead sponsor
Tectonic Operating Company, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 26, 2026, 10:49 AM EDT
Completed No phase listed Observational

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

NCT00370214
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
3 Months and older
Enrollment
3,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
54
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Not applicable Interventional Results available

Rheos® Pivotal Trial

NCT00442286
View directory record Official record
Conditions
Hypertension
Interventions
Rheos® Baroreflex Hypertension System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 2 Interventional

Combined Treatment of Resistant Hypertension and Atrial Fibrillation

NCT01117025
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
Interventions
Circumferential PV isolation, Circumferential PVI+renal denervation
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

NCT03541174
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Jun 26, 2026, 10:49 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

MANP in African Americans With Hypertension

NCT04542681
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Jun 26, 2026, 10:49 AM EDT
Terminated Not applicable Interventional

Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp)

NCT00477477
View directory record Official record
Conditions
Childhood Obesity, Dyslipidemia, Insulin Resistance, Hypertension
Interventions
Diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Jun 26, 2026, 10:49 AM EDT
Recruiting Not applicable Interventional

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

NCT06526858
View directory record Official record
Conditions
Resistant Hypertension
Interventions
HyperQureTM Renal Denervation (RDN) System:
Device
Lead sponsor
DeepQure Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Orange, California • Stanford, California • Gainesville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 26, 2026, 10:49 AM EDT
Terminated Phase 3 Interventional

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

NCT04857840
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Firibastat (QGC001) Period 1
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years to 99 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Not applicable Interventional Results available

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

NCT01897727
View directory record Official record
Conditions
Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions
Spironolactone, BP medication uptitration
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jun 26, 2026, 10:49 AM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Lifestyle Interventions in Treatment-Resistant Hypertension

NCT02342808
View directory record Official record
Conditions
Treatment-Resistant Hypertension
Interventions
Structured center-based lifestyle intervention, Standard education and physician advice
Behavioral
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jun 26, 2026, 10:49 AM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

NCT00455325
View directory record Official record
Conditions
Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions
Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

NCT04519658
View directory record Official record
Conditions
Resistant Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Saraland, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jun 26, 2026, 10:49 AM EDT
Active, not recruiting Not applicable Interventional

RADIANCE Continued Access Protocol

NCT05017935
View directory record Official record
Conditions
Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
Interventions
Renal Denervation
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Chula Vista, California • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Jun 26, 2026, 10:49 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

NCT00185705
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Dyslipidemia
Interventions
Telmisartan
Drug
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Jun 26, 2026, 10:49 AM EDT
Not yet recruiting Not applicable Interventional

The RESPLASH Study

NCT06880562
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Splanchnic Nerve Denervation, Renal Denervation Only
Device
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 26, 2026, 10:49 AM EDT
Withdrawn Not applicable Interventional

Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension

NCT00973531
View directory record Official record
Conditions
Sleep Apnea, Hypertension
Interventions
Autotitrating Positive Airway Pressure (APAP), Traditional Split Titration Polysomnogram
Device
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Jun 26, 2026, 10:49 AM EDT
Completed Phase 3 Interventional

Firibastat in Treatment-resistant Hypertension

NCT04277884
View directory record Official record
Conditions
Hypertension
Interventions
Firibastat, Placebo
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jun 26, 2026, 10:49 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133885
View directory record Official record
Conditions
Hypertension
Interventions
Minocycline Group, Placebo Group
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jun 26, 2026, 10:49 AM EDT